Trebble, T.; Stroud, M.A.; Arden, N.K.; Ballinger, A.; Fine, D.R.; Mullee, M.A.; Wootton, S.A.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA11
Academic Journal
Inflammation in Crohn's disease (CD) is mediated by mononuclear cells and is associated with increased production of TNF α and prostaglandin E2 (PGE[sub 2]). In active CD, dietary supplementation with fish oil results in anti-inflammatory effects associated with increases in eicosapentaenoic acid (EPA) and reductions in arachidonic acid (AA) concentrations in plasma. However, in the unsupplemented state the relationship between habitual dietary fat intake, EPA, and AA incorporation into mononuclear cells and TNF α/PGE2 production is uncertain. The fatty acid composition and synthetic function of peripheral blood mononuclear cells (PBMC) were determined in 53 CD patients, stratified into active and inactive disease groups by Crohn's Disease Activity Index, and age and sex-matched healthy controls. There were no differences between CD and controls in dietary fat or total energy intake. Lower concentrations of AA were noted in active CD (20.2%) v controls (24.0%) (p < 0.001) and inactive CD (20.2%) v controls (23.8%) (p < 0.001). Higher concentrations of EPA were noted in active CD (0.7%) and inactive CD (0.8%) vcontrols (0.3% for each control group; p = 0.001). α linolenic acid, the precursor of EPA, was increased in active CD v controls (p = 0.003) but no differences were noted in concentrations of the AA precursor, linoleic acid. Trends towards a reduction in PGE[sub 2] production were noted in inactive CD v controls, but no differences in production of TNF α were seen. CD is associated with alterations in the availability of AA and EPA in both active and inactive states. This cannot be simply explained by altered dietary intake but may be an adaptive or pathological response to the disease process. The anti-inflammatory response to dietary fish oil may reflect a pharmacological effect, and not the correction of a deficiency of EPA. The response of mononuclear cell composition and function to dietary fish oil warrants further investigation.


Related Articles

  • Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohn's disease. Eder, Piotr; Lykowska-Szuber, Liliana; Krela-Kazmierczak, Iwona; Stawczyk-Eder, Kamila; Sterzynska, Karolina; Iwanik, Katarzyna; Majewski, Przemyslaw; Zabel, Maciej; Linke, Krzysztof // Folia Histochemica et Cytobiologica;2013, Vol. 51 Issue 3, p239 

    It is not known if anti-tumor necrosis factor (anti-TNF) agents provoke only apoptosis of lamina propria mononuclear cells (LPMC) engaged in inflammatory processes or whether it's a general phenomenon concerning all LPMC. In this study we carried out an immunohistochemical analysis of the...

  • Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis. Kimura, Koji; Takayanagi, Risa; Yokoyama, Haruko; Yamada, Yasuhiko // Rheumatology International;Jan2012, Vol. 32 Issue 1, p145 

    In Japan, the recommended dosage regimens of infliximab (IFX) for treatment of rheumatoid arthritis (RA) and Crohn's disease (CD) are different. However, the differences have not been analyzed theoretically. In a previous study, we constructed a pharmacokinetic-pharmacodynamic model to...

  • Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. Juanola, Oriol; Moratalla, Alba; Gutiérrez, Ana; Sempere, Laura; Zapater, Pedro; Giménez, Paula; Almenta, Isabel; Peiró, Gloria; González-Navajas, José; Such, José; Francés, Rubén // Journal of Gastroenterology;Jul2015, Vol. 50 Issue 7, p758 

    Background: Anti-TNF-α therapies interact with the tolerogenic response in patients with Crohn's disease, modulating inflammation. However, drug levels and the genetic background may affect this interaction. Methods: Patients with Crohn's disease in remission on biologic monotherapy were...

  • Is there a Benefit from the Concomitant Use of Immunosupression with Anti-TNF in Crohn's Disease; Heads or Tails? Lakatos, Peter Laszlo // Reviews on Recent Clinical Trials;Sep2009, Vol. 4 Issue 3, p152 

    Over the last some years the increasing knowledge on the pathogenesis of Crohn's disease led to the development of a number of biological agents targeting specific molecules involved in gut inflammation, first of all TNF-a and its receptors. Infliximab, adalimumab and certolizumab have been...

  • Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn’s disease. Sorrentino, Dario; Avellini, Claudio; Beltrami, Carlo Alberto; Pasqual, Enrico; Zearo, Ester // International Journal of Colorectal Disease;May2006, Vol. 21 Issue 3, p276 

    Although infliximab has been shown to improve the clinical course of Crohn’s disease, its effect on intestinal strictures is controversial. We describe the case of a woman with steroid-resistant colonic Crohn’s disease presenting with intermittent obstruction because of a tight...

  • Anti-tumour necrosis factor therapy in Crohn's disease: where are we now? van Deventer, S.J.H. // Gut;Sep2002, Vol. 51 Issue 3, p362 

    Background: Although familial clusters of Barrett's oesophagus and oesophageal adenocarcinoma have been reported, a familial predisposition to these diseases has not been systematically investigated. Aims: To determine whether Barrett's oesophagus and oesophageal (or oesophagogastric junctional)...

  • TNF-α −308A promoter polymorphism is associated with enhanced TNF-α production and inflammatory activity in Crohn’s patients with fistulizing disease. González, Segundo; Rodrigo, Luis; Martínez-Borra, Jesús; López-Vázquez, Antonio; Fuentes, Dolores; Niño, Pilar; Cadahía, Valle; Saro, Cristina; Dieguez, M. Angeles; López-Larrea, Carlos // American Journal of Gastroenterology;May2003, Vol. 98 Issue 5, p1101 

    : ObjectiveTumor necrosis factor-α (TNF-α) plays a key role in the inflammatory response and pathogenesis of Crohn’s disease (CD). TNF-α −308A polymorphism within the TNF-α gene promoter has been associated with enhanced TNF-α production in vitro. The aim of this...

  • Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Borruel, N.; Carol, M.; Casellas, F.; Antolín, M.; de Lara, F.; Espín, E.; Naval, J.; Guarner, F.; Malagelada, J.R. // Gut;Nov2002, Vol. 51 Issue 5, p659 

    Background and aims: Tumour necrosis factor α (TNF-α) plays a key role in the pathogenesis of intestinal inflammation in Crohn's disease. The effect of bacteria on TNF-α release by intestinal mucosa was investigated. Methods: Ileal specimens were obtained at surgery from 10 patients...

  • In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Atreya, Raja; Neumann, Helmut; Neufert, Clemens; Waldner, Maximilian J; Billmeier, Ulrike; Zopf, Yurdagül; Willma, Marcus; App, Christine; Münster, Tino; Kessler, Hermann; Maas, Stefanie; Gebhardt, Bernd; Heimke-Brinck, Ralph; Reuter, Eva; Dörje, Frank; Rau, Tilman T; Uter, Wolfgang; Wang, Thomas D; Kiesslich, Ralf; Vieth, Michael // Nature Medicine;Mar2014, Vol. 20 Issue 3, p313 

    As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for molecular mTNF imaging in this disease. Topical antibody administration in 25 patients with Crohn's disease led to detection of...


Read the Article


Sign out of this library

Other Topics